24小时热门版块排行榜

返回列表

zlwcw

木虫 (著名写手)

应助: 1 (幼儿园)
金币: 2021.1
散金: 225
红花: 8
帖子: 1274
在线: 219.7小时
虫号: 530429
注册: 2008-03-21
性别: GG
专业: 代谢性疾病药物药理

[交流] 【转帖】查尔斯河拟16亿美元收购无锡药明康德已有14人参与

查尔斯河拟16亿美元收购无锡药明康德
2010-04-26 11:18:47　来源: 网易财经　跟贴 1 条手机看股票网易财经4月26日讯据消息人士透露，美国查尔斯河试验室国际公司（Charles River Laboratories International Inc），同意以16亿美元收购无锡药明康德新药开发有限公司。

查尔斯河每股21.25美元的收购价，包括11.25美元的现金支付和10美元的股票购买价。据消息人士透露收购，双方将会在今天晚些时候正式公布交易。之前已经有媒体报道双方有意进行交易，但是目前双方的公司发言人均拒绝发布评论。

摩根大通和瑞信集团分别担任查尔斯河以及无锡药明康德的顾问公司。在这宗收购完成之后，无锡药明康德将持有公司少于30%的股份。(冯易尘）

Charles River Plans to Acquire WuXi AppTec

April, 26, 2010 - Charles River is pleased to announce plans to acquire WuXi AppTec, creating the only global CRO to offer fully integrated drug development services from molecule creation to first-in-human testing. The combined company, which will retain the name Charles River, will offer enhanced support for your research programs through our comprehensive portfolio of early-stage drug development services and expanded global presence.

WuXi AppTec is a leading drug research and development outsourcing company with significant expertise in discovery chemistry.  It was established in 2000 and has steadily grown to more than 4,000 employees with operations in China and the United States. Together with Charles River, a leading global provider of both research models and associated services as well as preclinical drug development services, the combined company will have 12,000 employees, providing unparalleled support for your early-stage drug development needs.

We regard this as a transformational transaction that creates value for customers by enabling you to obtain comprehensive support for your early-stage drug development needs from one company with extensive scientific expertise, depth and breadth.  Further, we will be able to provide you with expanded global access to our integrated portfolio of products and services, enabling you to work within or across the locales you choose, in North America, Europe or China.

This strategic combination brings together two companies with the shared mission of supporting the acceleration of your drug development efforts and a commitment to exceeding your expectations.

We will continue to share additional details in the next few days on how Charles River will set a new standard in the outsourced drug development services industry. In the meantime, please view more information on www.criver.com, or contact your sales representative with any questions.

We look forward to continuing to work with you and to further supporting your early-stage drug development needs.



Forward-Looking Statements

This document includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on current expectations and beliefs of Charles River Laboratories International, Inc. (Charles River) and WuXi PharmaTech (Cayman) Inc. (WuXi), and involve a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: 1) the possibility that the companies may be unable to obtain stockholder or regulatory approvals required for the combination; 2) problems may arise in successfully integrating the businesses of the two companies; 3) the acquisition may involve unexpected costs; 4) the combined company may be unable to achieve cost synergies; 5) the businesses may suffer as a result of uncertainty surrounding the acquisition; and 6) the industry may be subject to future regulatory or legislative actions and other risks that are described in Securities and Exchange Commission (SEC) reports filed or furnished by Charles River and WuXi.

Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River and WuXi. Charles River and WuXi assume no obligation and expressly disclaim any duty to update information contained in this filing except as required by law.

Additional Information

This document may be deemed to be solicitation material in respect of the proposed combination of Charles River and WuXi. In connection with the proposed transaction, Charles River will file a preliminary proxy statement and a definitive proxy statement with the SEC. The information contained in the preliminary filing will not be complete and may be changed. Before making any voting or investment decisions, investors and security holders are urged to read the definitive proxy statement when it becomes available and any other relevant documents filed with the SEC because they will contain important information. The definitive proxy statement will be mailed to the shareholders of Charles River seeking their approval of the proposed transaction. Charles River’s shareholders will also be able to obtain a copy of the definitive proxy statement free of charge by directing a request to: Charles River Laboratories, 251 Ballardvale Street, Wilmington, MA 01887, Attention: General Counsel. In addition, the preliminary proxy statement and definitive proxy statement will be available free of charge at the SEC’s website, www.sec.gov or shareholders may access copies of the documentation filed with the SEC by Charles River on Charles River’s website at www.criver.com.

Charles River and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Charles River’s directors and executive officers is available in Charles River’s proxy statement for its 2010 annual meeting of shareholders, which was filed with the SEC on March 30, 2010. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of Charles River shareholders in connection with the proposed transaction will be set forth in the preliminary proxy statement when it is filed with the SEC.

This document does not constitute an offer of any securities for sale or a solicitation of an offer to buy any securities. The Charles River shares to be issued in the proposed transaction have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Charles River intends to issue such Charles River shares pursuant to the exemption from registration set forth in Section 3(a)(10) of the Securities Act.

[ Last edited by zlwcw on 2010-4-26 at 21:34 ]

回复此楼